Visual Impairment in Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Creator
Timothy McCulley; Jinglan Pei; Paris Sidiropoulos; Christine Birchwood; Jennie Best; John Stone; Sebastian Unizony
Affiliation
(TM) The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; (JP) (PS) (CB) (JB) Genentech, Inc., South San Francisco, California; (JS) (SU) Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, Massachusetts
Subject
Vascular Disorders
Description
The GiACTA trial demonstrated the efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) [1]. However, the effectiveness of TCZ for prevention of specific GCA-related visual manifestations is currently unknown. The incidence of GCA-related visual manifestations was analyzed in patients treated with TCZ in a real-world setting.
Date
2019-03
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2019 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS 2019: Scientific Platform III
Collection
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Publisher
Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416